How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?

Rheumatology (Oxford). 2018 Apr 1;57(4):591-593. doi: 10.1093/rheumatology/kex016.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Biological Factors / therapeutic use*
  • Biological Products / therapeutic use*
  • Humans
  • Immune System Diseases / drug therapy*
  • Rare Diseases*
  • Treatment Outcome

Substances

  • Biological Factors
  • Biological Products